Skip to content

Innoviva, Inc. INVA Intangible Purchases

Intangible Purchases at other companies

Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
$1.49M+128%
Organon logo
OrganonOGN
$0-100%
ANI Pharmaceuticals logo
ANI PharmaceuticalsANIP
$5.25M-69.8%
Zymeworks logo
ZymeworksZYME
$0-100%
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
$5M-66.7%

Other financials

Income statement

See full
Revenue$98.0M+10.6%
Gross profit$75.8M+3.4%
Operating income$38.2M-7.9%
Net income$186.6M+501%
EPS (diluted)$2.22+400%

Balance sheet

See full
Cash & equivalents$603.1M+89.0%
Total debt$269.4M-40.3%
Total equity$1.3B
Total assets$1.8B+46.4%

Cash flow

See full
Operating cash flow$35.3M-27.4%
CapEx$492.0K
Free cash flow$34.8M-28.4%

Valuation

See full
Market cap$1.74B+51.8%

Profitability

See full
Gross margin73.7%-9.9pp
Operating margin38.1%-11.2pp
Net margin119.9%+107pp
FCF margin54.1%+5.3pp

Returns & leverage

See full
Return on equity29.1%
Debt / equity0.2×
Current ratio21.1×+18.7×

Where this comes from

Reported directly by Innoviva, Inc. in its filing.

Tagged under the XBRL concept us-gaap:PaymentsToAcquireIntangibleAssets.

The official record: Innoviva, Inc.’s 10-K, filed February 25, 2026, on SEC EDGAR. View the filing →

Ask your AI about Innoviva, Inc.'s intangible purchases.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Innoviva, Inc.'s intangible purchases?
Innoviva, Inc. (INVA) reported intangible purchases of $0 in Q4 2025.
How has Innoviva, Inc.'s intangible purchases changed year-over-year?
Innoviva, Inc.'s intangible purchases decreased by 100.0% year-over-year, from $1M to $0.
What does intangible purchases mean?
Cash spent acquiring intangible assets such as patents, licenses, and other intellectual property.